

---

## Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

---

Published on 08/05/2021

### COVID-19 Genomics and Precision Public Health Weekly Update Content

- Pathogen and Human Genomics Studies
- Non-Genomics Precision Health Studies
- News, Reviews and Commentaries

### Pathogen and Human Genomics Studies

- Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.  
(<https://pubmed.ncbi.nlm.nih.gov/34320281>)

Bergwerk Moriah et al. The New England journal of medicine 2021 7

Among fully vaccinated health care workers, the occurrence of breakthrough infections with SARS-CoV-2 was correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

- Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose (<https://www.medrxiv.org/content/10.1101/2021.07.26.21261130v1>)  
MA Gram et al, MEDRXIV, July 28, 2021

A total of 144,360 were vaccinated with the ChAdOx1 vaccine as the first dose and of these 136,551 individuals received an mRNA vaccine as the second dose. A total of 1,691,464 person-years and 83,034 cases of SARS-CoV-2 infection were included. The VE against SARS-CoV-2 infection when combining the ChAdOx1 and an mRNA vaccine was 88% (95% confidence interval (CI): 83; 92) 14 days after the second dose and onwards. There were no COVID-19 related hospitalizations and deaths among the individuals vaccinated with the combination of the ChAdOx1 and an mRNA vaccine during the study period.

- Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine  
(<https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1>)

SJ Thomas et al, MEDRXIV, July 28, 2021

- The trans-omics landscape of COVID-19. (<https://pubmed.ncbi.nlm.nih.gov/34315889>)

Wu Peng et al. Nature communications 2021 7 (1) 4543

We collect blood samples from 231 COVID-19 patients, prefiltered to exclude those with selected comorbidities, yet with symptoms ranging from asymptomatic to critically ill. Using integrative analysis of genomic, transcriptomic, proteomic, metabolomic and lipidomic profiles, we report a trans-omics landscape for COVID-19. Our analyses find neutrophils heterogeneity between asymptomatic and critically ill patients. Meanwhile, neutrophils over-activation, arginine depletion and tryptophan metabolites accumulation correlate with T cell dysfunction in critical patients

- Integrative genomic analyses identify susceptibility genes underlying COVID-19 hospitalization.

(<https://pubmed.ncbi.nlm.nih.gov/34315903>)

Pathak Gita A et al. Nature communications 2021 7 (1) 4569

Despite rapid progress in characterizing the role of host genetics in SARS-Cov-2 infection, there is limited understanding of genes and pathways that contribute to COVID-19. Here, we integrate a genome-wide association study of COVID-19 hospitalization (7,885 cases and 961,804 controls from COVID-19 Host Genetics Initiative) with mRNA expression, splicing, and protein levels (n = 18,502). We identify 27 genes related to inflammation and coagulation pathways whose genetically predicted expression was associated with COVID-19 hospitalization

- An implementation science approach to evaluating pathogen whole genome sequencing in public health

(<https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-021-00934-7>)

AS Ferdinand et al, Genome Medicine, July 29, 2021

We developed the Pathogen Genomics in Public Health Surveillance Evaluation (PG-PHASE) Framework to guide examination of the use of WGS in public health surveillance and disease control. We illustrate the use of this framework with three pathogens as case studies: *Listeria monocytogenes*, *Mycobacterium tuberculosis* and SARS-CoV-2.

- Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings – Barnstable County, Massachusetts, July 2021

([https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s\\_cid=mm7031e2\\_e&ACSTrackingID=USCDC\\_921-](https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_e&ACSTrackingID=USCDC_921-DM62612&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20July%2030%2C%202021&deliveryName=USCDC_921-DM62612)

[DM62612&ACSTrackingLabel=MMWR%20Early%20Release%20-](https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_e&ACSTrackingID=USCDC_921-DM62612&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20July%2030%2C%202021&deliveryName=USCDC_921-DM62612)

[%20Vol.%2070%2C%20July%2030%2C%202021&deliveryName=USCDC\\_921-DM62612](https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_e&ACSTrackingID=USCDC_921-DM62612&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20July%2030%2C%202021&deliveryName=USCDC_921-DM62612)

[CM Brown et al, MMWR, July 30,2021](https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_e&ACSTrackingID=USCDC_921-DM62612&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20July%2030%2C%202021&deliveryName=USCDC_921-DM62612)

CM Brown et al, MMWR, July 30,2021

In July 2021, following multiple large public events in a Barnstable County, Massachusetts, town, 469 COVID-19 cases were identified among Massachusetts residents who had traveled to the town during July 3–17; 346 (74%) occurred in fully vaccinated persons. Testing identified the Delta variant in 90% of specimens from 133 patients. Cycle threshold values were similar among specimens from patients who were fully vaccinated and those who were not.

- Impact of B.1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort study

(<https://www.medrxiv.org/content/10.1101/2021.07.28.21261285v1>)

B Lefevre et al, MEDRXIV July 31, 2021

We observed reduced vaccine effectiveness associated with B.1.351, as well as B.1.351 outbreaks in two LTCFs among individuals who had received two doses of vaccine. Our findings highlight the need to maintain SARS-CoV-2 surveillance in these high-risk settings beyond the current COVID-19 mass vaccination campaign, and advocate for a booster vaccine dose prior to the next winter season.

- Myocarditis and Pericarditis After Vaccination for COVID-19

(<https://jamanetwork.com/journals/jama/fullarticle/2782900>)

GA Diaz et al, JAMA, August 4, 2021

Forty hospitals in Washington, Oregon, Montana, and Los Angeles County, California, that were part of the Providence health care system and used the same electronic medical record (EMR) were included. All patients with documented COVID-19 vaccinations administered inside the system or recorded in state registries at any time through May 25, 2021, were identified. Two distinct self-limited syndromes, myocarditis and pericarditis, were observed after COVID-19 vaccination. Myocarditis developed rapidly in younger patients, mostly after the second vaccination. Pericarditis affected older patients later, after either the first or second dose.

## Non-Genomics Precision Health Studies

- Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.

(<https://pubmed.ncbi.nlm.nih.gov/34320281>)

Bergwerk Moriah et al. The New England journal of medicine 2021 7

Among fully vaccinated health care workers, the occurrence of breakthrough infections with SARS-CoV-2 was correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

- Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose (<https://www.medrxiv.org/content/10.1101/2021.07.26.21261130v1>)

MA Gram et al, MEDRXIV, July 28, 2021

A total of 144,360 were vaccinated with the ChAdOx1 vaccine as the first dose and of these 136,551 individuals received an mRNA vaccine as the second dose. A total of 1,691,464 person-years and 83,034 cases of SARS-CoV-2 infection were included. The VE against SARS-CoV-2 infection when combining the ChAdOx1 and an mRNA vaccine was 88% (95% confidence interval (CI): 83; 92) 14 days after the second dose and onwards. There were no COVID-19 related hospitalizations and deaths

among the individuals vaccinated with the combination of the ChAdOx1 and an mRNA vaccine during the study period.

- Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine (<https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1>)  
SJ Thomas et al, MEDRXIV, July 28, 2021

- The trans-omics landscape of COVID-19. (<https://pubmed.ncbi.nlm.nih.gov/34315889>)  
Wu Peng et al. Nature communications 2021 7 (1) 4543

We collect blood samples from 231 COVID-19 patients, prefiltered to exclude those with selected comorbidities, yet with symptoms ranging from asymptomatic to critically ill. Using integrative analysis of genomic, transcriptomic, proteomic, metabolomic and lipidomic profiles, we report a trans-omics landscape for COVID-19. Our analyses find neutrophils heterogeneity between asymptomatic and critically ill patients. Meanwhile, neutrophils over-activation, arginine depletion and tryptophan metabolites accumulation correlate with T cell dysfunction in critical patients

- Integrative genomic analyses identify susceptibility genes underlying COVID-19 hospitalization. (<https://pubmed.ncbi.nlm.nih.gov/34315903>)  
Pathak Gita A et al. Nature communications 2021 7 (1) 4569

Despite rapid progress in characterizing the role of host genetics in SARS-Cov-2 infection, there is limited understanding of genes and pathways that contribute to COVID-19. Here, we integrate a genome-wide association study of COVID-19 hospitalization (7,885 cases and 961,804 controls from COVID-19 Host Genetics Initiative) with mRNA expression, splicing, and protein levels (n = 18,502). We identify 27 genes related to inflammation and coagulation pathways whose genetically predicted expression was associated with COVID-19 hospitalization

- An implementation science approach to evaluating pathogen whole genome sequencing in public health (<https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-021-00934-7>)  
AS Ferdinand et al, Genome Medicine, July 29, 2021

We developed the Pathogen Genomics in Public Health Surveillance Evaluation (PG-PHASE) Framework to guide examination of the use of WGS in public health surveillance and disease control. We illustrate the use of this framework with three pathogens as case studies: *Listeria monocytogenes*, *Mycobacterium tuberculosis* and SARS-CoV-2.

- Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings – Barnstable County, Massachusetts, July 2021 ([https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s\\_cid=mm7031e2\\_e&ACSTrackingID=USCDC\\_921-DM62612&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20July%2030%2C%202021&deliveryName=USCDC\\_921-DM62612](https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_e&ACSTrackingID=USCDC_921-DM62612&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20July%2030%2C%202021&deliveryName=USCDC_921-DM62612))  
CM Brown et al, MMWR, July 30, 2021

In July 2021, following multiple large public events in a Barnstable County, Massachusetts, town, 469 COVID-19 cases were identified among Massachusetts residents who had traveled to the town during July 3–17; 346 (74%) occurred in fully vaccinated persons. Testing identified the Delta variant in 90% of specimens from 133 patients. Cycle threshold values were similar among specimens from patients who were fully vaccinated and those who were not.

- Impact of B.1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort study (<https://www.medrxiv.org/content/10.1101/2021.07.28.21261285v1>)  
B Lefevre et al, MEDRXIV July 31, 2021

We observed reduced vaccine effectiveness associated with B.1.351, as well as B.1.351 outbreaks in two LTCFs among individuals who had received two doses of vaccine. Our findings highlight the need to maintain SARS-CoV-2 surveillance in these high-risk settings beyond the current COVID-19 mass vaccination campaign, and advocate for a booster vaccine dose prior to the next winter season.

- Myocarditis and Pericarditis After Vaccination for COVID-19 (<https://jamanetwork.com/journals/jama/fullarticle/2782900>)  
GA Diaz et al, JAMA, August 4, 2021

Forty hospitals in Washington, Oregon, Montana, and Los Angeles County, California, that were part of the Providence health care system and used the same electronic medical record (EMR) were included. All patients with documented COVID-19 vaccinations administered inside the system or recorded in state registries at any time through May 25, 2021, were identified. Two distinct self-limited syndromes, myocarditis and pericarditis, were observed after COVID-19 vaccination. Myocarditis developed rapidly in younger patients, mostly after the second vaccination. Pericarditis affected older patients later, after either the first or second dose.

## News, Reviews and Commentaries

- Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. (<https://pubmed.ncbi.nlm.nih.gov/34320281>)  
Bergwerk Moriah et al. The New England journal of medicine 2021 7

Among fully vaccinated health care workers, the occurrence of breakthrough infections with SARS-CoV-2 was correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

- Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose (<https://www.medrxiv.org/content/10.1101/2021.07.26.21261130v1>)  
MA Gram et al, MEDRXIV, July 28, 2021

A total of 144,360 were vaccinated with the ChAdOx1 vaccine as the first dose and of these 136,551 individuals received an mRNA vaccine as the second dose. A total of 1,691,464 person-years and 83,034 cases of SARS-CoV-2 infection were included. The VE against SARS-CoV-2 infection when combining the ChAdOx1 and an mRNA vaccine was 88% (95% confidence interval (CI): 83; 92) 14 days after the second dose and onwards. There were no COVID-19 related hospitalizations and deaths among the individuals vaccinated with the combination of the ChAdOx1 and an mRNA vaccine during the study period.

- Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine (<https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1>)  
SJ Thomas et al, MEDRXIV, July 28, 2021

- The trans-omics landscape of COVID-19. (<https://pubmed.ncbi.nlm.nih.gov/34315889>)  
Wu Peng et al. Nature communications 2021 7 (1) 4543

We collect blood samples from 231 COVID-19 patients, prefiltered to exclude those with selected comorbidities, yet with symptoms ranging from asymptomatic to critically ill. Using integrative analysis of genomic, transcriptomic, proteomic, metabolomic and lipidomic profiles, we report a trans-omics landscape for COVID-19. Our analyses find neutrophils heterogeneity between asymptomatic and critically ill patients. Meanwhile, neutrophils over-activation, arginine depletion and tryptophan metabolites accumulation correlate with T cell dysfunction in critical patients

- Integrative genomic analyses identify susceptibility genes underlying COVID-19 hospitalization. (<https://pubmed.ncbi.nlm.nih.gov/34315903>)  
Pathak Gita A et al. Nature communications 2021 7 (1) 4569

Despite rapid progress in characterizing the role of host genetics in SARS-Cov-2 infection, there is limited understanding of genes and pathways that contribute to COVID-19. Here, we integrate a genome-wide association study of COVID-19 hospitalization (7,885 cases and 961,804 controls from COVID-19 Host Genetics Initiative) with mRNA expression, splicing, and protein levels (n = 18,502). We identify 27 genes related to inflammation and coagulation pathways whose genetically predicted expression was associated with COVID-19 hospitalization

- An implementation science approach to evaluating pathogen whole genome sequencing in public health (<https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-021-00934-7>)  
AS Ferdinand et al, Genome Medicine, July 29, 2021

We developed the Pathogen Genomics in Public Health Surveillance Evaluation (PG-PHASE) Framework to guide examination of the use of WGS in public health surveillance and disease control. We illustrate the use of this framework with three pathogens as case studies: *Listeria monocytogenes*, *Mycobacterium tuberculosis* and SARS-CoV-2.

- Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings – Barnstable County, Massachusetts, July 2021

([https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s\\_cid=mm7031e2\\_e&ACSTrackingID=USCDC\\_921-DM62612&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20July%2030%2C%202021&deliveryName=USCDC\\_921-DM62612](https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_e&ACSTrackingID=USCDC_921-DM62612&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20July%2030%2C%202021&deliveryName=USCDC_921-DM62612))  
CM Brown et al, MMWR, July 30, 2021

In July 2021, following multiple large public events in a Barnstable County, Massachusetts, town, 469 COVID-19 cases were identified among Massachusetts residents who had traveled to the town during July 3–17; 346 (74%) occurred in fully vaccinated persons. Testing identified the Delta variant in 90% of specimens from 133 patients. Cycle threshold values were similar among specimens from patients who were fully vaccinated and those who were not.

- Impact of B.1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort study  
(<https://www.medrxiv.org/content/10.1101/2021.07.28.21261285v1>)  
B Lefevre et al, MEDRXIV July 31, 2021

We observed reduced vaccine effectiveness associated with B.1.351, as well as B.1.351 outbreaks in two LTCFs among individuals who had received two doses of vaccine. Our findings highlight the need to maintain SARS-CoV-2 surveillance in these high-risk settings beyond the current COVID-19 mass vaccination campaign, and advocate for a booster vaccine dose prior to the next winter season.

- Myocarditis and Pericarditis After Vaccination for COVID-19  
(<https://jamanetwork.com/journals/jama/fullarticle/2782900>)  
GA Diaz et al, JAMA, August 4, 2021

Forty hospitals in Washington, Oregon, Montana, and Los Angeles County, California, that were part of the Providence health care system and used the same electronic medical record (EMR) were included. All patients with documented COVID-19 vaccinations administered inside the system or recorded in state registries at any time through May 25, 2021, were identified. Two distinct self-limited syndromes, myocarditis and pericarditis, were observed after COVID-19 vaccination. Myocarditis developed rapidly in younger patients, mostly after the second vaccination. Pericarditis affected older patients later, after either the first or second dose.

**Disclaimer:** Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

Page last updated: Aug 05, 2021

Content source: Office of Genomics and Precision Public Health (<http://www.cdc.gov/genomics/>), CDC Office of Science (<https://www.cdc.gov/od/science/index.htm>)